Use of an innovative pre-formed structural scaffold for reconstruction of segmental bone loss in a zygomaticomaxillary complex model
Active Grant Awarded
- Award ID
- R44DE035431
- Recipient
-
Revbio, Inc. UEI ZBTLVWJKASA8
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,276,407
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 8% complete
- Place of performance
- Lowell, MA 01854, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Dental and Craniofacial Research awarded Revbio, Inc. of Lowell, Massachusetts a grant with $1.276407 million obligated on September 23, 2026, under Assistance Listing 93.121, Oral Diseases and Disorders Research. The funded project, "Use of an Innovative Pre-Formed Structural Scaffold for Reconstruction of Segmental Bone Loss in a Zygomaticomaxillary Complex Model," develops Tetranite (TN), a patented mineral-organic bone adhesive. TN is composed of tetracalcium phosphate and phosphoserine mixed with an aqueous solution to form a self-setting, flowable adhesive (TN-FA). The source describes TN cast into pre-formed anatomical shapes with engineered porosity and reinforced with resorbable microfibers to serve as a load-bearing graft for comminuted and segmental craniomaxillofacial defects. The project aims to avoid the multiple surgical sites and donor-site morbidity associated with autogenous vascularized bone. The source states that TN bonds chemically to bone and metal and gains immediate strength within minutes, and that phosphoserine released during resorption over several months enhances bone regeneration. The period of performance runs from September 23, 2026 to August 31, 2028, and work takes place in Lowell, Massachusetts 01854. The parent program funds basic, translational, and clinical research in dental, oral, and craniofacial health through grants and cooperative agreements.
Description
- Abstract
- There is a distinct need for a material to facilitate reconstruction of complex craniomaxillofacial (CMF) fractures, including comminuted and segmental defects where bone has been damaged beyond repair due to severe trauma. This is commonly seen in blast injuries and high energy impact injuries in a younger population as well as subsequent to falls, which is a high risk in the aging population. Current treatments generally seek to reconstruct these defects with autogenous vascularized bone requiring multiple surgical sites and procedures. Additionally, these procedures require technical microvascular expertise and a longer healing time as there are secondary donor site requirements. This translates into increased risk of complication including flap loss/failure, infection, pain, hardware extrusion and continuing morbidity of the donor site. In polytraumatic injuries, donor site availability may be limited. To address this problem, revbio has developed tetranite® (TN), a patented mineral-organic bone adhesive that can act as a load-bearing, regenerative construct to stabilize and rebuild missing and comminuted bone resulting from these complex injuries. TN is comprised of tetracalcium phosphate and phosphoserine, mixed with an aqueous solution to form a self-setting, flowable adhesive (tetranite flowable adhesive or TN-FA). Unlike other cements or grafts, TN is cohesive and tacky to bone in a wet field, resulting in robust chemical adhesion to bone and metal, providing immediate strength within minutes. The bone regeneration process is enhanced by the osteo-stimulative effect of phosphoserine, released during TN's resorption process over the course of several months.TN is cast into pre-formed anatomical shapes with engineered porosity, reinforced with resorbable microfibers to provide a load-bearing graft (tetranite structural scaffold or TN-SS) that can bridge large segmental bone defects as an osteoconductive scaffold. TN-SS can be loaded with antibiotics for local release to minimize post-operative infection. TN-FA is used to bond fragments and/or TN-SS into the defect in a single stage procedure.TN-FA and TN-SS are packaged together as TN resorbable engineered bone adhesive reconstruction (TN-REBAR). The results from the summative user handling cadaver study (aim 2) and the pivotal large animal study (aim 3) will be submitted to FDA in an IDE application to initiate clinical studies. Long term, revbio's mission is to commercialize TN to revolutionize approaches to segmental bone loss in the craniofacial complex, as well as throughout the skeleton. We aim to offer surgeons and patients a safer, more effective alternative treatment that is designed to reduce pain, accelerate return to function, and significantly decrease the complication rates associated with current procedures to reconstruct segmental bone loss following severe, complex facial fractures.
Quick answers
Who received award R44DE035431?
R44DE035431 was awarded to Revbio, Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 23, 2026.
How much is award R44DE035431 worth?
$1,276,407 has been obligated on R44DE035431.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award